What is Adaptimmune Therapeutics plc?
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 6.89M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.